S&P 500   3,150.29 (+1.05%)
DOW   28,024.05 (+1.25%)
QQQ   205.03 (+1.28%)
AAPL   270.78 (+1.96%)
FB   200.93 (+0.79%)
MSFT   151.37 (+0.96%)
GOOGL   1,340.74 (+1.65%)
AMZN   1,752.17 (-0.48%)
CGC   18.66 (+0.32%)
NVDA   211.65 (+1.06%)
MU   48.02 (+3.00%)
BABA   201.66 (+0.83%)
GE   10.98 (+1.76%)
TSLA   337.34 (+1.29%)
T   38.29 (+0.26%)
AMD   39.59 (-0.25%)
NFLX   306.25 (+0.63%)
DIS   147.94 (+0.34%)
S&P 500   3,150.29 (+1.05%)
DOW   28,024.05 (+1.25%)
QQQ   205.03 (+1.28%)
AAPL   270.78 (+1.96%)
FB   200.93 (+0.79%)
MSFT   151.37 (+0.96%)
GOOGL   1,340.74 (+1.65%)
AMZN   1,752.17 (-0.48%)
CGC   18.66 (+0.32%)
NVDA   211.65 (+1.06%)
MU   48.02 (+3.00%)
BABA   201.66 (+0.83%)
GE   10.98 (+1.76%)
TSLA   337.34 (+1.29%)
T   38.29 (+0.26%)
AMD   39.59 (-0.25%)
NFLX   306.25 (+0.63%)
DIS   147.94 (+0.34%)
S&P 500   3,150.29 (+1.05%)
DOW   28,024.05 (+1.25%)
QQQ   205.03 (+1.28%)
AAPL   270.78 (+1.96%)
FB   200.93 (+0.79%)
MSFT   151.37 (+0.96%)
GOOGL   1,340.74 (+1.65%)
AMZN   1,752.17 (-0.48%)
CGC   18.66 (+0.32%)
NVDA   211.65 (+1.06%)
MU   48.02 (+3.00%)
BABA   201.66 (+0.83%)
GE   10.98 (+1.76%)
TSLA   337.34 (+1.29%)
T   38.29 (+0.26%)
AMD   39.59 (-0.25%)
NFLX   306.25 (+0.63%)
DIS   147.94 (+0.34%)
S&P 500   3,150.29 (+1.05%)
DOW   28,024.05 (+1.25%)
QQQ   205.03 (+1.28%)
AAPL   270.78 (+1.96%)
FB   200.93 (+0.79%)
MSFT   151.37 (+0.96%)
GOOGL   1,340.74 (+1.65%)
AMZN   1,752.17 (-0.48%)
CGC   18.66 (+0.32%)
NVDA   211.65 (+1.06%)
MU   48.02 (+3.00%)
BABA   201.66 (+0.83%)
GE   10.98 (+1.76%)
TSLA   337.34 (+1.29%)
T   38.29 (+0.26%)
AMD   39.59 (-0.25%)
NFLX   306.25 (+0.63%)
DIS   147.94 (+0.34%)
Log in

NASDAQ:CNSP - CNS Pharmaceuticals Stock Price, Forecast & News

$4.10
+0.02 (+0.49 %)
(As of 12/6/2019 01:20 PM ET)
Today's Range
$4.01
Now: $4.10
$4.11
50-Day Range N/A
52-Week Range
$3.86
Now: $4.10
$5.69
Volume1,402 shs
Average Volume132,917 shs
Market Capitalization$64.42 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
CNS Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, focuses on the development of anti-cancer drug candidates for the treatment of primary and metastatic brain, and central nervous system tumors. Its lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma. The company was founded in 2017 and is based in Houston, Texas.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CNSP
CUSIPN/A
CIKN/A
Phone800-946-9185

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$64.42 million
Next Earnings DateN/A
OptionableNot Optionable

Receive CNSP News and Ratings via Email

Sign-up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter.


CNS Pharmaceuticals (NASDAQ:CNSP) Frequently Asked Questions

What is CNS Pharmaceuticals' stock symbol?

CNS Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNSP."

What is the consensus analysts' recommendation for CNS Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CNS Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for CNS Pharmaceuticals.

Has CNS Pharmaceuticals been receiving favorable news coverage?

Media headlines about CNSP stock have trended neutral recently, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. CNS Pharmaceuticals earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for CNS Pharmaceuticals.

Who are some of CNS Pharmaceuticals' key competitors?

What other stocks do shareholders of CNS Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CNS Pharmaceuticals investors own include Editas Medicine (EDIT), DURECT (DRRX), Diffusion Pharmaceuticals (DFFN), Curis (CRIS), Clovis Oncology (CLVS), BIOLINERX LTD/S (BLRX), Bed Bath & Beyond (BBBY), Air Transport Services Group (ATSG), Amarin (AMRN) and Advanced Micro Devices (AMD).

When did CNS Pharmaceuticals IPO?

(CNSP) raised $9 million in an initial public offering (IPO) on Friday, November 8th 2019. The company issued 2,100,000 shares at $4.00-$5.00 per share. Benchmark served as the underwriter for the IPO.

When does the company's quiet period expire?

CNS Pharmaceuticals' quiet period expires on Wednesday, December 18th. CNS Pharmaceuticals had issued 2,125,000 shares in its IPO on November 8th. The total size of the offering was $8,500,000 based on an initial share price of $4.00. During the company's quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of CNS Pharmaceuticals?

Shares of CNSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is CNS Pharmaceuticals' stock price today?

One share of CNSP stock can currently be purchased for approximately $4.10.

How big of a company is CNS Pharmaceuticals?

CNS Pharmaceuticals has a market capitalization of $64.42 million. View Additional Information About CNS Pharmaceuticals.

What is CNS Pharmaceuticals' official website?

The official website for CNS Pharmaceuticals is http://cnspharma.com/.

How can I contact CNS Pharmaceuticals?

CNS Pharmaceuticals' mailing address is 2100 WEST LOOP SOUTH SUITE 900, HOUSTON TX, 77027. The company can be reached via phone at 800-946-9185 or via email at [email protected]


MarketBeat Community Rating for CNS Pharmaceuticals (NASDAQ CNSP)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  8 (Vote Outperform)
Underperform Votes:  9 (Vote Underperform)
Total Votes:  17
MarketBeat's community ratings are surveys of what our community members think about CNS Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNSP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel